Riskpilot← Back to searchSign inGet full accessBuzzard Pharmaceuticals AB
ABActiveOrg 5590736855Skeppsbron 16Research and experimental development on natural sciences and engineering · NACE 7210Est. 20161-4 employees
Revenue 2024
SEK 0
EBITDA margin
—
-68% vs 2023
Equity ratio
98.5%
Financial strength
Net profit 2024
SEK -658K
-216% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK 321K | -68% |
| Net profit | SEK -658K | -216% |
| Total assets | SEK 131,9M | +6% |
| Equity | SEK 129,9M | +8% |
| Employees | — | — |
Legal name
Buzzard Pharmaceuticals AB
Org number
5590736855
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
24 augusti 2016
Share capital
SEK 67 491
Employees
1-4
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget ska bedriva forskning, utveckling och kommersialisering av läkemedel och därmed förenlig verksamhet.
Address
Skeppsbron 16
Email
dechateau@buzzardpharma.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 16 | 38 | 12 | 30 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — | — | −1 247 | −1 243 |
| EBITDA | −331 | −716 | −586 | −620 | −1 277 | −875 | 1 010 | 321 |
| Depreciation & amort. | −166 | −655 | −1 222 | −1 227 | −1 468 | −1 606 | −1 349 | −1 052 |
| EBIT | −497 | −1 371 | −1 808 | −1 847 | −2 745 | −2 481 | −339 | −731 |
| Net financials | — | — | — | — | — | 37 | 131 | 73 |
| Profit before tax | −497 | −1 371 | −1 808 | −1 847 | −2 745 | −2 444 | −208 | −658 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | — | — |
| Net profit | −497 | −1 371 | −1 808 | −1 847 | −2 745 | −2 444 | −208 | −658 |
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Total assets | 2 297 | 7 101 | 18 234 | 30 167 | 76 237 | 134 088 | 124 488 | 131 890 |
| Equity | 2 053 | 6 682 | 16 874 | 23 028 | 71 754 | 120 782 | 120 574 | 129 918 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | — | — |
| Short-term debt | 244 | 419 | 1 360 | 7 139 | 4 483 | 13 306 | 3 914 | 1 972 |
| Total debt | 244 | 419 | 1 360 | 7 139 | 4 483 | 13 306 | 3 914 | 1 972 |
EBITDA margin
32147100.0%
This company
15.8%
Market median
+203462558% vs market
20172024
Equity ratio
98.5%
This company
38.2%
Market median
+158% vs market
20172024
Return on equity
-0.5%
This company
18.4%
Market median
-103% vs market
20172024
Net profit margin
-65769300.0%
This company
8.1%
Market median
-811966767% vs market
20172024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20172024
Debt / equity
0.02×
This company
0.62×
Market median
+97% vs market
20172024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2016-08-01 – 2017-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
BC Audit | Audit | 2020 | — | — |
MD Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2025 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Chairman | 2020 | — | — | |
| Deputy Board Member | 2020 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Buzzard Pharmaceuticals AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Bo Christer Eriksson | Audit | 0 companies |
| Maarten De Chateau | Chief Executive Officer | 0 companies |
| Carl-Johan Spak | Board of Directors | 0 companies |
| Thomas Bengt Eldered | Board of Directors | 0 companies |
| Göran Mattias Häggblom | Board of Directors | 0 companies |
| Lars Urban Paulsson | Chairman | 0 companies |
| Sonja Agneta Nylöf | Deputy Board Member | 0 companies |